SC
IMMU

Sculptor Capital’s Immunomedics Inc IMMU Stock Holding History

Sculptor Capital’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-93,900
Closed -$829K – 429
2017
Q2 		$829K Sell
93,900
-28,900
-24% -$203K ﹤0.01% 255
2017
Q1 		$795K Buy
+122,800
New +$622K ﹤0.01% 246

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Sculptor Capital's IMMU Position: Q3 2017 in Review

Sculptor Capital sold out of Immunomedics Inc (IMMU) in Q3 2017, closing a stake of 93,900 shares — an estimated $829K sold.

Sculptor Capital first reported a position in IMMU in Q1 2017 and held it in 2 quarters. The position peaked at $829K in Q2 2017. 150 funds tracked by Wall St. Rank hold IMMU as of Q3 2017.

  • Sculptor Capital reported no remaining Immunomedics Inc position as of Q3 2017 after selling out during the quarter.
  • Sculptor Capital sold 93,900 Immunomedics Inc shares in Q3 2017, an estimated $829K.
  • Sculptor Capital first reported a position in Immunomedics Inc in Q1 2017 and held it in 2 quarters.
  • Sculptor Capital's Immunomedics Inc position peaked at $829K in Q2 2017.
  • 150 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2017.

Based on Sculptor Capital's 13F filing for Q3 2017, filed 13 Nov 2017.